CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)
Industrials › Services-Commercial Physical & Biological Research
Price History
Feb 9, 2026 — Apr 4, 2026Investment Snapshot
- Trading 102% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 7/9 — financially strong with improving fundamentals
- ROE of 6.4% — below-average profitability
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) is a Industrials company operating in Services-Commercial Physical & Biological Research, listed on the NYSE , with a market capitalisation of $7.7 billion . Key value metrics: P/E ratio 37.9, P/B ratio 2.42, Piotroski F-Score 7 out of 9 (strong financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. — Fundamental Analysis Summary
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) is currently trading 102% above its Graham Number of $77.02, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 37.9x.
On financial health, CRL shows a strong Piotroski F-Score of 7/9, indicating improving fundamentals across profitability, leverage, and efficiency, and modest return on equity of 6.4% (sector average: 5.5%), and elevated leverage with a debt-to-equity ratio of 1.05.
StockPik's composite Value Score for CRL is 57/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
CRL shows revenue declining at 1% year-over-year, with earnings declining at 750%.